Oleg Lipatov

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.8K citations

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.4K citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen et al. · Journal of Clinical Oncology · 2013 · 438 citations · Full text